Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

Cancer

Volumn 120, Issue 5, 2014, Pages 692-701

  Grivas, Petros D ^a   Daignault, Stephanie ^b   Tagawa, Scott T ^c   Nanus, David M ^c   Stadler, Walter M ^d   Dreicer, Robert ^e   Kohli, Manish ^f   Petrylak, Daniel P ^g   Vaughn, David J ^h   Bylow, Kathryn A ⁱ   Wong, Steven G ^j   Sottnik, Joseph L ^b   Keller, Evan T ^b   Al Hawary, Mahmoud ^b   Smith, David C ^a   Hussain, Maha ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f MAYO CLINIC   (United States)

^g YALE CANCER CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ MEDICAL COLLEGE OF WISCONSIN   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

angiogenesis; bladder cancer; chemotherapy; maintenance therapy; sunitinib; urothelial carcinoma

Indexed keywords

ALKALINE PHOSPHATASE; CREATININE; PLACEBO; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; BLADDER BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTENSION; HYPONATREMIA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUTROPENIA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT PLANNING; URINARY TRACT INFECTION; VERY ELDERLY;

ANGIOGENESIS; BLADDER CANCER; CHEMOTHERAPY; MAINTENANCE THERAPY; SUNITINIB; UROTHELIAL CARCINOMA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PYRROLES; SAMPLE SIZE; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84896703767     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28477     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Yafi FA, North S, Kassouf W,. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol. 2011; 18: e25-e34.
3. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602-4608.
4. Ferrara N, Gerber HP, LeCouter J,. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676.
5. Dickinson AJ, Fox SB, Persad RA, et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol. 1994; 74: 762-766.
6. Ferrara N, Davis-Smyth T,. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18: 4-25.
7. Yang CC, Chu KC, Yeh WM,. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol. 2004; 22: 1-6.
8. Izawa JI, Slaton JW, Kedar D, et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep. 2001; 8: 9-15.
9. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D,. VEGF receptor expression and signaling in human bladder tumors. Oncogene. 2003; 22: 3361-3370.
10. Inoue K, Slaton JW, Davis DW, et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 2000; 6: 2635-2643.
11. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012; 13: 810-816.
12. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM,. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2: 471-478.
13. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-337.
14. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003; 20: 757-766.
15. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-1338.
16. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
17. Blumenthal GM, Cortazar P, Zhang JJ, et al. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist. 2012; 17: 1108-1113.
18. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP,. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. 2009; 27: 391-399.
19. Yoon CY, Lee JS, Kim BS, et al. Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J Urol. 2011; 52: 55-63.
20. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007; 5: 32.
21. Simon R, Wittes RE, Ellenberg SS,. Randomized phase II clinical trials. Cancer Treat Rep. 1985; 69: 1375-1381.
22. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010; 28: 1373-1379.
23. Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011; 22: 2646-2653.
24. Galsky MD, Moshier EL, Krege S, et al. Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy [abstract]. J Clin Oncol. 2013: 31 (suppl 6): Abstract 256.
25. Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013; 11: 175-181.
26. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011; 29: 1525-1530.
27. Balar AV, Apolo AB, Ostrovnaya I, et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013; 31: 724-730.
28. Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012; 30: 507-512.
29. Krege S, Rexer H, vom Dorp F, et al. Prospective randomized double-blind multicenter phase II study comparing chemotherapy with gemcitabine and cisplatin plus sorafenib vs gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer-SUSE-(AUO-AB 31/05) [published online ahead of print September 5, 2013]. BJU Int. doi: 10.1111/bju.12437.].
30. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009; 6: 327-338.
31. Patel PH, Chadalavada RS, Ishill NM, et al. Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) [abstract]. J Clin Oncol. 2008; 26: 15S. Abstract 5008.
32. Battinelli EM, Markens BA, Italiano JE Jr,. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011; 118: 1359-1369.
33. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 2007; 13: 2643-2650.